Know Cancer

or
forgot password

Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients: Prospective Treatment Trial With Topical Glycolic Acid and HPV Genotype Characterization


N/A
7 Years
N/A
Not Enrolling
Both
Flat Warts (Diagnosis), HIV Infections

Thank you

Trial Information

Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients: Prospective Treatment Trial With Topical Glycolic Acid and HPV Genotype Characterization


Inclusion Criteria:



- Male or female HIV-positive patients 7 years of age or older with at least 15 flat
warts, diagnosed clinically by one dermatologist (RLM), on the face and/or dorsal
hands were included in the study.

Exclusion Criteria:

- Key exclusion criteria included current use of potential wart treatments or other
topical OTC products on the affected area(s).

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Treatment efficacy of 15% glycolic acid lotion for flat warts

Outcome Description:

Our primary objective is to determine the efficacy of 15% glycolic acid lotion for improving the cosmetic appearance of flat warts in HIV infected children and young adults on antiretroviral therapy.

Outcome Time Frame:

Patients were evaluated every two weeks for eight weeks and monthly for the next eight weeks, for a total monitoring period of 16 weeks.

Safety Issue:

No

Authority:

United States: Institutional Review Board

Study ID:

P30 AI 045008

NCT ID:

NCT01289171

Start Date:

January 2009

Completion Date:

October 2010

Related Keywords:

  • Flat Warts (Diagnosis)
  • HIV Infections
  • The efficacy, tolerability and safety of 15% glycolic acid lotion for treatment of diffuse flat warts among HIV+ children were investigated
  • HIV Infections
  • Acquired Immunodeficiency Syndrome
  • Epidermodysplasia Verruciformis
  • Warts

Name

Location